One Kendall Square
Building 300, Suite 201
United States

Tel: 617.914.8420

Email: info@AVROBIO.com

Show jobs for this employer


AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR RD 01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases.

We are headquartered in Cambridge, MA and have offices in Toronto, ON. Please visit our website www.avrobio.com for more information on who we are, what we care about and how we are bringing these therapies to our patients.

160 articles about AVROBIO